|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | Grand Central Station, PO Box 4777 |
Address2 |
|
| City | New York |
State | NY |
Zip Code | 10163 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104060-12
|
||||||||
|
6. House ID# 432920001
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Mason Zeagler |
Date | 4/17/2025 10:00:34 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
General Parkinson's disease Information, including information on symptoms, health coverage, health costs, social determinants of health, data collection, research, environmental risks, and health access for underserved communities.
Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66) - requires the U.S. Department of Health and Human services to produce an integrated national plan to prevent, diagnose, treat, and cure Parkinsons, ameliorate symptoms, and slow or stop progression. This plan will encompass Parkinsons disease and all other neurodegenerative Parkinsonisms, such as multiple system atrophy, corticobasal degeneration, progressive supranuclear palsy, and Parkinsons-related dementia.
The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.
Clinical Trials Modernization Act (to be reintroduced): seeks to improve participation in clinical research trials by removing economic barriers faced by patients. The legislation would allow HHS to issue grants or enter in contractual arrangements to support education, outreach, and recruitment for clinical trials and address financial barriers faced by patients, including excluding renumeration for participation in clinical trials from taxable income.
Conrad State 30 and Physician Access Reauthorization Act (to be reintroduced): Reauthorizes the Conrad State 30 program and improves policies to address health care provider shortages, supporting neurological care for Parkinson's patients.
Centralizing and prioritizing neurodegenerative disease research within the National Institutes of Health.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Health & Human Services - Dept of (HHS), President of the U.S., General Services Administration (GSA), Office of Science & Technology Policy (OSTP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mason |
Zeagler |
|
|
|
Dustin |
Watson |
|
|
|
Drew |
Hatter |
|
|
|
Sallie |
Weart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Lobbying to increase the affordability and accessibility of treatments for Parkinsons disease.
Alleviating Barriers for Caregivers (ABC) Act (to be reintroduced): requires the Centers for Medicare & Medicaid Services (CMS) and Social Security to simplify processes and communications for family caregivers to assist individuals in accessing and utilizing benefits.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mason |
Zeagler |
|
|
|
Drew |
Hatter |
|
|
|
Dustin |
Watson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
General Education on Parkinson's Risk Factors: Focused on raising awareness about triggers and risks of Parkinson's disease, including exposure to TCE, paraquat, air pollution, and other environmental chemicals.
Banning environmental risk factors of Parkinsons disease, including paraquat.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Drew |
Hatter |
|
|
|
Dustin |
Watson |
|
|
|
Mason |
Zeagler |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for implementation of Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No: 118-66).
Funding for discretionary, non-defense priorities including overall investment in the National Institute of Health, ARPA-H, and Centers for Disease Control and Prevention within the FY 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills.
Funding for the Parkinson's Research Program (PRP) under the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP) within the FY 2025 and FY 2026 Defense Appropriation bills.
Funding for the Parkinsons Disease Research, Education and Clinical Centers under the Department of Veterans Affairs within the FY 2025 and FY 2026 Military Construction, Veterans Affairs and Related Agencies Appropriation bills.
Funding for the National Neurological Conditions Surveillance System under the Centers for Disease Control and Prevention within the FY 2025 and FY 2026 Labor, Health and Human Services, Education, and Related Agencies Appropriation bills.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Disease Control & Prevention (CDC), Defense - Dept of (DOD), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dustin |
Watson |
|
|
|
Sallie |
Weart |
|
|
|
Drew |
Hatter |
|
|
|
Mason |
Zeagler |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Increasing the affordability and accessibility of treatments for Parkinsons disease.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mason |
Zeagler |
|
|
|
Dustin |
Watson |
|
|
|
Drew |
Hatter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
General education on the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Defense - Dept of (DOD), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dustin |
Watson |
|
|
|
Sallie |
Weart |
|
|
|
Mason |
Zeagler |
|
|
|
Drew |
Hatter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
Lobbying to ban the use of known environmental risk factors of Parkinsons disease, including Trichloroethylene (TCE) and paraquat, in the United States.
S.J.Res.19/H.J.Res.27/ H.J.Res.34 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Environmental Protection Agency relating to ""Trichloroethylene (TCE); Regulation Under the Toxic Substances Control Act (TSCA)""
The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (to be reintroduced): creates a Centers of Excellence grant program within the National Institutes of Health to conduct and support of research, training, and health information dissemination with respect to environmental risk factors of neurodegenerative diseases, including Parkinsons disease.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mason |
Zeagler |
|
|
|
Drew |
Hatter |
|
|
|
Dustin |
Watson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Clinical Trials Modernization Act (to be reintroduced): seeks to improve participation in clinical research trials by removing economic barriers faced by patients. The legislation would allow HHS to issue grants or enter in contractual arrangements to support education, outreach, and recruitment for clinical trials and address financial barriers faced by patients, including excluding renumeration for participation in clinical trials from taxable income.
Credit for Caring Act (to be reintroduced): seeks to amend the Internal Revenue Code of 1986 to provide a nonrefundable credit for working family caregivers.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Drew |
Hatter |
|
|
|
Dustin |
Watson |
|
|
|
Mason |
Zeagler |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |